Access Official Technical PDF

Share Summary:LinkedInEmail

Medical device manufacturing depends on more than production capacity. Regulation, product identification and access to suitable technologies all influence whether devices can move from development into the market. In 2017, Germany’s medtech industry continued to grow, but its results fell short of expectations as companies prepared for major regulatory changes and explored the potential of digitalization.

The figures and outlook discussed here reflect the industry context reported in 2018. They offer a useful view of how regulatory readiness and operational capability were already becoming connected concerns for medical device manufacturers.

Medical device manufacturing amid measured growth

German medical technology companies recorded revenue of €29.9 billion in 2017, a 2.4% increase over the previous year. The sector had expected to exceed €30 billion, but missed that milestone by a narrow margin. The number of businesses with more than 20 employees rose to 1,310, while employment increased to 137,857. At the time, the industry association Spectaris forecast growth of 4% for 2018.

These results show an industry that remained an important part of the German economy while facing uneven growth. The report also noted weaker export activity to several markets, including the United States, China, France, Italy and the United Kingdom. The reasons differed by market, with regulatory requirements, sales controls, political uncertainty and Brexit-related concerns among the factors discussed.

For manufacturers, such conditions make operational planning especially important. Production and product availability depend not only on demand, but also on the ability to satisfy market-specific requirements and maintain the processes needed to bring devices to market.

MDR readiness puts regulatory capacity in focus

The European Medical Device Regulation (MDR) had entered into force a year before the 2018 report, but companies still faced open questions about practical implementation. The industry was concerned that rising administrative demands could make compliance more difficult. A particular concern was the availability of notified bodies, such as DEKRA and TÜV SÜD, which assess certain products before manufacturers can place them on the market.

The potential consequences extend beyond regulatory teams. The report warned that if notified-body capacity became increasingly constrained, manufacturers could face delays or be unable to market products. It also raised the possibility of economic losses, reduced business activity, job losses and innovations failing to reach patients.

For engineering and operations leaders, this highlights the importance of treating regulatory requirements as part of the product and production lifecycle—not as a final administrative checkpoint. Design, documentation, manufacturing and market access are interdependent. When assessment capacity is limited, unclear or incomplete preparation can add pressure to an already demanding process.

Connect compliance work to production processes

A practical response is to make regulatory responsibilities visible across the functions involved in product development and manufacture. Engineering, quality, operations and regulatory teams need a shared understanding of the evidence and product information required for their work. This does not remove the need for external assessment, but it can help organizations identify dependencies and prepare their processes for regulatory review.

Manufacturers should also consider whether product identification and production records support the traceability expected of their devices. The report highlighted Unique Device Identification (UDI) as an important requirement under the new European regulation, noting that manufacturers would need to identify their products unambiguously. Suitable technologies are therefore part of the implementation effort.

UDI makes identification and traceability a production concern

UDI links the regulatory need for unique product identification with the practical realities of manufacturing and product handling. Manufacturers need to consider how identification is applied and how product information remains associated with the device. The source material does not prescribe a particular technology or system, but it makes clear that companies need appropriate tools to meet identification requirements.

For plant and quality teams, that means considering UDI alongside production planning and quality assurance. The relevant questions include where identification fits into the manufacturing workflow, which teams are responsible for product data, and how the organization will maintain consistency between the product and its associated information. These are implementation questions that should be addressed in coordination with regulatory and engineering functions.

Digitalization offers opportunity—and adds responsibility

Digitalization was identified as a potential source of new business models and growth for the healthcare sector. The industry expected policy measures supporting e-health to create additional momentum. At the same time, the report noted that German manufacturers could offer more technologically advanced solutions than existing conditions allowed.

Connected medical products also bring cybersecurity into the operational picture. The publication quoted the president of Germany’s Federal Institute for Drugs and Medical Devices, who emphasized that manufacturers, operators and users must give greater attention to the IT security of networked medical devices. Digital capability, therefore, cannot be considered independently of product safety and the responsibilities of the organizations that make and use connected devices.

For industrial automation professionals, the broader lesson is to evaluate digital initiatives in the context of the complete product and care environment. Connectivity may support new applications, but the people and organizations involved must also consider security and the requirements governing medical products.

Conclusion: align technology with market readiness

The 2018 industry outlook described a growing German medtech sector confronting regulatory uncertainty, concerns about notified-body capacity and the need to implement UDI. Digitalization offered opportunities, while connected devices brought cybersecurity into sharper focus.

For medical device manufacturing teams, the practical priority is coordination. Regulatory preparation, product identification, production processes and digital security should be considered together. Investing in appropriate technologies matters, but so does ensuring that the people responsible for design, quality and operations understand how those technologies support compliant, traceable products and their route to market.

Access Official Technical PDF

About The Author